Everolimus

Everolimus (Afinitor®), which received FDA approval on 26 February 2016;

• In cancers originating in the lung that cannot be surgically removed and have spread to surrounding or distant tissues (metastatic)
• In well-differentiated (showing the characteristics of the tissue of origin), nonfunctional gastrointestinal system (stomach – intestinal system) neuroendocrine tumors it is used.

Particularly in postmenopausal patients with hormone receptor-positive, HER2 (epidermal growth gene)-negative breast cancer , Everolimus exerts its effect by disabling the molecular pathway called mTOR, which enables cancer cell growth and uncontrolled proliferation. Its most common side effects are mucosal inflammation, infection, redness, rash, diarrhea, swelling and abdominal pain.